Seegene released a new influenza A sub-type screening test, Seeplex FluA ACE Subtyping, that enables simultaneous detection of pandemic novel influenza A (H1N1), seasonal human influenza A H1, seasonal human influenza A H3, and avian influenza A H5 in a single reaction. Currently, screening kits available to national health organizations test separately for one viral strain, some using the immunochromatography method, commonly known as rapid test. This testing methodology is not being adopted as a standard method due to its low accuracy. The Seeplex FluA ACE subtyping test is based on the company’s novel DPO-based Multiplex RT-PCR technology. Seegene USA, 866-733-4949, www.seegene.com